Pharming Shareholders appoint Sijmen de Vries as new CEO
Sijmen de Vries, MD, MBA, is a 48-year old Dutch national, with extensive senior level experience in both the pharmaceutical and biotechnology industries. He joins Pharming from Swiss-based 4-Antibody where he was CEO. Dr de Vries has also been CEO of Morphochem and prior to this spent many years at Novartis and at SmithKline Beecham Pharmaceuticals where he held senior business and commercial positions. Dr de Vries also holds non-executive directorships in two private life science companies.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.